|Systematic (IUPAC) name|
|ATC code||A04AD13 (WHO)|
|Molar mass||616.26 g/mol[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
Casopitant (trade names Rezonic (US), Zunrisa (EU)) is an neurokinin 1 (NK1) receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV). It is currently under development by GlaxoSmithKline (GSK).
In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
|45px||This drug article relating to the gastrointestinal system is a stub. You can help ssf by expanding it.|
|35px||This drug article relating to the nervous system is a stub. You can help ssf by expanding it.|
- Lohr L (2008). "Chemotherapy-induced nausea and vomiting". Cancer J. 14 (2): 85–93. doi:10.1097/PPO.0b013e31816a0f07. PMID 18391612.
- "GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa" (PDF). London: EMEA. 13 October 2009. Retrieved 21 December 2009.